Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

3 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Efficacy and Safety of ADVAIR DISKUS Plus Spiriva HandiHaler Versus Spiriva HandiHaler in COPD NCT00784550 - Subject Diary

- 05-12-20 - 1 Formulier, 3 Itemgroepen, 16 Data-elementen, 1 Taal
Itemgroepen: Administrative Data, Subject Daily Diary, Medical Problems/Medication taken
Study ID: 111114 Clinical Study ID: 111114 Study Title: A Randomized, Double-Blind, Parallel-Group, 24-Week Study to Evaluate the Efficacy and Safety of ADVAIR™ DISKUS™ (Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Inhalation Powder) BID Plus Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg) QD Versus Spiriva QD Plus Placebo DISKUS BID in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00784550 https://clinicaltrials.gov/ct2/show/NCT00784550 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: N/A Trade Name: Tiotropium Bromide, Fluticasone Propionate/Salmeterol Study Indication: Pulmonary Disease, Chronic Obstructive The purpose of the study is to determine the efficacy and safety of the combination of ADVAIR DISKUS® 250/50mcg (FLUTICASONE PROPIONATE/SALMETEROL COMBINATION PRODUCT) plus SPIRIVA® HANDIHALER® inhaler 18mcg (TIOTROPIUM) compared to SPIRIVA® HANDIHALER® inhaler 18mcg (TIOTROPIUM) in patients with COPD. There are a total of 6 visits: Screening (Visit 1), Randomization (Visit 2), and after 4 (Visit 3), 8 (Visit 4), 16 (Visit 5) and 24 (Visit 6) weeks of treatment. This form (Subject Diary) is to be filled out by study participant between Visit 1 (Screening) and Visit 2 (Randomization), between Visit 2 (Randomization) and Visit 3, between Visit 3 and Visit 4, between Visit 4 and Visit 5 and between Visit 5 and Visit 6. Daily Diary Instructions: Reminders: (for patient) - Bring this Diary and all study medication to each clinic visit. - Do not take any new medications without first contacting the study doctor. - Do not write your name or initials anywhere on this diary. (paper-pen specific) - Withhold albuterol for at least 6 hours prior to your next clinic visit. If you have taken albuterol within 6 hours prior to a visit, contact the clinic to reschedule the visit. - Complete the Medical Problems/Medications Taken Worksheet if you experience any medical problems and take medication(s) for the problem(s). - Withhold your morning dose of blinded study medication prior to the next clinic visit. IF you have taken your morning dose of blinded study medication prior to a visit contact the clinic to reschedule the visit. (NOT applicable for Subject Diary 1) - Record all medical problems which may have occurred on that date, AND all medication(s) you (the subject) took on that date to treat the problem. General rules for Diary completion: - Print neatly using only black or blue ink. Do NOT use pencil. (paper-pen specific) - Draw one line through any changes or mistakes and re-enter the correct information above/beside. (paper-pen specific) - DO NOT use correction fluid or tape. (paper-pen specific) Record the following information in this diary every day. 1. Date. Record dates in DD MMM YY format (for example: 15. OCT 08). 2. Daily Albuterol Use. If you required rescue albuterol for COPD symptoms during the last 24 hour period, record the total number of puffs administered. If none, enter zero (0). 3. Daily Albuterol Nebel Use. If you required rescue albuterol nebulas for COPD symptoms during the last 24 hour period, record the total number of nebulas administered. If none, enter zero (0). 4.1. Morning (AM) Study Medication Taken. Each morning (approximately 6:00-9:00 AM) take 1 inhalation from the SPIRIVA HANDIHALER Device. Record the total number of inhalations of open-blind study medication you took each day from the SPIRIVA HANDIHALER Device. (applicable only for Subject Diary 1) 4.2. Morning (AM) and Evening (PM) Study Medication Taken. Each morning (approximately 6:00-9:00 AM) take 1 inhalation from the DISKUS followed by 1 inhalation from the SPIRIVA HANDIHALER Device. Each evening (approximately 6:00-9:00 PM) approximately 12 hours after the morning dosing with the DISKUS, take 1 inhalation from the DISKUS. Record the total number of inhalations of double-blind study medication you took each day from the DISKUS and the total number of inhalations of open-blind study medication you took each day from the SPIRIVA HANDIHALER Device. (applicable for Subject Diaries 2-5) 5. Medical Problems/Medications Taken Worksheet. Record all medical problems which may have occurred on that date, AND all medication(s) you took on that date to treat the problem on the separate Medical Problems/Medication Taken Worksheet page. Do not include study-related medications.

Safety, reactogenicity and immunogenicity 10-valent pneumococcal conjugate vaccine compared to Prevenar™, co-administration of DTPw-HBV/Hib and OPV or IPV vaccines in infants, NCT00344318 - Diary card

- 15-04-19 - 1 Formulier, 6 Itemgroepen, 42 Data-elementen, 1 Taal
Itemgroepen: Administrative data, Local symptoms, Other local symptoms, General Symptoms, Other general symptoms, Medication
Study ID: 107007 Clinical Study ID: 107007 Study Title: A phase IIIb randomized, double-blind, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine compared to Prevenar™, when co-administered with DTPw-HBV/Hib and OPV or IPV vaccines as a 3-dose primary immunization course during the first 6 months of age. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00344318 https://clinicaltrials.gov/ct2/show/NCT00344318 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Pneumococcal conjugate vaccine GSK1024850A Trade Name: Prevenar, Tritanrix-HepB, Hiberix, Polio Sabin., Poliorix Study Indication: Infections, Streptococcal This study consists of 2 groups of probands (Children of 6-10-14 weeks or 2-4-6 months of age are included): One group receive a 3-dose primary vaccination with the GSK Biologicals' (10-valent) pneumococcal conjugate vaccine. The other group r eceive a 3-dose primary vaccination with Prevenar™. All probands receive DTPw-HBV/Hib and OPV or IPV vaccines. Ths study consists of 3 workbooks (WB): WB 1: The WB 1 consists 4 visits (all in active phase): Visit 1, Timing: Month 0; Age for 6-12 weeks scheduled Visit 2, Timing: Month 1; Age for 10 weeks scheduled Visit 3, Timing: Month 2; Age for 14 weeks scheduled Visit 4, Timing: Month 3; Age for +/- 4 months scheduled Intervals between the visits: Visit 1 to Visit 2: 28-42 days, Visit 2 to Visit 3: 28-42 days, Visit 3 to Visit 4: 30-42 days WB 2: The WB 2 consists 4 visits (all in active phase): Visit 1, Timing: Month 0; Age for 6-12 weeks scheduled Visit 2, Timing: Month 2; Age for +/- 4 months scheduled Visit 3, Timing: Month 4; Age for +/- 6 months scheduled Visit 4, Timing: Month 5; Age for +/- 7 months scheduled Intervals between the visits: Visit 1 to Visit 2: 49-83 days, Visit 2 to Visit 3: 49-83 days, Visit 3 to Visit 4: 30-42 days WB 3: The WB 3 consists the phone contact (6 months safety follow-up), Timing: Month 8 or 10. This document contains Diary card form. It has to be filled in of subject.

Safety, tolerability and pharmacodynamics of Elubrixin in cystic fibrosis patients, NCT00903201 - Subject Diary Card

- 05-03-20 - 1 Formulier, 8 Itemgroepen, 41 Data-elementen, 1 Taal
Itemgroepen: Administrative data, Emergency, Diary card, Study drug, Exacerbations, Other medications, Changes in health, Daily Respiratory Symptom Diary for Cystic Fibrosis
Study ID: 110399 Clinical Study ID: 110399 Study Title: A randomized, double blind, parallel group, placebo controlled 28 day study to investigate the safety, tolerability and pharmacodynamics of SB-656933 in subjects with cystic fibrosis. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00903201 https://clinicaltrials.gov/ct2/show/NCT00903201?term=NCT00903201 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: SB656933, Placebo Trade Name: N/A Study Indication: Cystic Fibrosis The study consists of a screening, five study visits and a follow-up (time relative to Baseline in days): Visit 1: Screening, Day -28 to -16 Visit 2a: Day -7 to -4 Visit 2b: Day 1 Visit 3: Day 14 Visit 4: Day 21 Visit 5: Day 28 Visit 6: Early Withdrawal/ Follow-up, Day 35 to 42. From day 1 to day 28 the patients will receive daily doses. This document contains the Subject Diary Card form. It has to be filled in at day 2-13, day 15-20 and day 22-27.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial